All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
VELDONA® interferon-alpha formulation has shown potential as a treatment candidate for feline chronic gingivostomatitis and canine atopic dermatitis
Ainos advances its product pipeline as it targets commencing clinical studies during the second quarter of 2023
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| AIMD | 0.5223 | +0.0012 | +0.23% |
| Ainos Inc | |||
/A%20concept%20image%20showing%20binary%20code%20with%20the%20ERROR%20message_%20Image%20by%20Danich%20Marmai%20via%20Shutterstock_.jpg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Quantum%20Computing/Image%20by%20Funtap%20via%20Shutterstock.jpg)